Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...

Objectives This study aimed to evaluate the Disease Activity index for PSoriatic Arthritis (DAPSA) based on a quick quantitative C reactive protein (qCRP) assay (Q-DAPSA) in a multicentre, prospective ...

Having questions, doubts, and fears is a natural part of dealing with psoriatic arthritis. However, excessive negative thoughts can lead to depression and impact the quality of your daily life.

If you have psoriatic arthritis (PsA) and you’re having trouble falling or staying asleep, you’re not alone. As frustrating as it can be to toss and turn at night, this doesn’t have to be ...

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory ...

Switching to Humira biosimilars saved Navitus clients more than $315 million in upfront costs in 2024 and resulted in a 60% ...

reade.nl Objective Data regarding cardiovascular comorbidity and cardiovascular risk factors in patients with psoriatic arthritis (PsA) are limited. To evaluate the cardiovascular risk profile, a ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

Psoriatic disease overall was bidirectionally associated with uveitis, with patients with uveitis at an increased risk of developing psoriatic arthritis and psoriasis. Psoriatic diseases are ...

Background Long-term effectiveness of tumour necrosis factor alpha inhibitors (TNFi) has mainly been explored in patients with rheumatoid arthritis (RA) and the data available on patients with ...

Martin added, “With this approval, pharmacies can substitute Hadlima for the reference product Humira without ... with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis ...